Movalis pills 15mg №20

Pills

Composition

1 pill contains meloxicam 15 mg;
Excipients: sodium citrate; lactose; MCC; polyvidone; colloidal anhydride silica; crospolyvidone; Magnesium stearate.

Packing

20 pcs.

Mechanism of action

NSAIDs. It belongs to the class of oxycams, is a derivative of enolic acid. It has anti-inflammatory, analgesic and antipyretic effects. The mechanism of action is associated with a decrease in the biosynthesis of prostaglandins as a result of the inhibition of the enzymatic activity of COX. At the same time, Movalis has a more active effect on COX-2, which participates in the synthesis of prostaglandins in the inflammatory focus, which reduces the risk of side effects on the upper gastrointestinal tract and slightly affects COX-1.
At the same time, meloxicam does not affect the synthesis of proteoglycan by chondrocytes of articular cartilage, does not affect the development of spontaneous arthrosis in rats and mice, which indicates its chondroneutrality.

Indications and usage

Symptomatic treatment:
- rheumatoid arthritis;
- osteoarthritis;
- ankylosing spondylitis.

Contraindications

- peptic ulcer of the stomach and duodenum in the acute phase;
- severe liver dysfunction;
- renal failure (without hemodialysis);
- pregnancy;
- lactation (breastfeeding);
- children's and teenage age up to 15 years;
- Hypersensitivity to meloxicam and other NSAIDs (including salicylates).
- Movalis for i / m injections should not be prescribed to patients receiving anticoagulants, given the possible risk of developing intramuscular hematoma;
- Movalis is not prescribed to patients in whom, in connection with the prescription of Acetylsalicylic acid or other NSAIDs, attacks of bronchial asthma, nasal mucous membrane polyps, angioedema, urticaria were observed.

Pregnancy and Breastfeeding

Although there was no teratogenic effect in preclinical trials, Movalis should not be prescribed during pregnancy and lactation.

the drug is prescribed in a daily dose of 7.5 mg.
Have patients with moderate renal failure (CC more than 25 ml / min) dose reduction is not required.
Tablets should be taken with food, washed down with water or another drink.

Adverse reactions

Gastrointestinal: > 1% - dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea; 0.1-1% - transient changes in liver function indicators (including increased transaminase or bilirubin levels), belching, esophagitis, ulcerative lesions of the gastrointestinal tract, latent or macroscopically visible Gastrointestinal bleeding; Hemic and lymphatic: > 1% - anemia; 0.1-1% - change in hemogram, incl. change in the number of individual types of leukocytes, leukopenia, thrombocytopenia.
Dermatologic: > 1% - itching, rash; 0.1-1% - stomatitis, urticaria; <0.1% - photosensitivity.
Allergic reactions: in some cases - bullous reactions, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Respiratory: Nervous system: > 1% - headache; 0.1-1% - dizziness, tinnitus, drowsiness; Cardiovascular: > 1% edema; 0.1-1% - increased blood pressure, palpitations, hot flashes.
Urogenital: 0.1-1% - change in renal function (increased creatinine and / or urea in the blood); less than 0.1% - acute renal failure; in some cases - interstitial nephritis, glomerulonephritis, renal medullary necrosis, nephrotic syndrome.
Special senses: Allergic reactions:

Special notes

Movalis should be used with caution in concomitant diseases of the upper GI tract, as well as in patients receiving anticoagulant therapy. In case of peptic ulcer or gastrointestinal bleeding, the drug should be discontinued.
With the appointment of Movalis, it is possible to develop gastrointestinal bleeding, ulcerative lesions or perforations, both with and without indications of previous symptoms and episodes of such complications in the gastrointestinal tract in patients.In older age, there is a more severe course of these complications.
Particular attention should be paid to patients who have had undesirable effects on the skin and mucous membranes, in such cases, should be considered to discontinue Movalis.
NSAIDs inhibit the synthesis of renal prostaglandins, which are involved in maintaining a sufficient level of renal blood flow. The prescription of NSAIDs in patients with reduced renal blood flow and BCC can accelerate renal decompensation, however, after discontinuation of NSAID therapy, the kidney function is usually restored to its previous level.
Particularly high risk of adverse reactions in patients with symptoms of dehydration, with congestive heart failure, liver cirrhosis, nephrotic syndrome and severe kidney disease, in patients receiving diuretics, as well as undergoing significant surgery, leading to hypovolemia. From the very beginning of treatment, such patients require careful control of urine output and kidney function.
In rare cases, an increase in serum transaminase levels or changes in other indicators of liver function have been reported. In most cases, deviations from the norm were minor and transient. With a more pronounced or persistent nature of impaired liver function indicators, discontinuation of Movalis should be discontinued and control laboratory studies should be conducted.
Patients with clinically non-progressive cirrhosis of the liver do not need to lower the dose.
Weakened and exhausted patients can tolerate side effects harder, such patients should be carefully monitored.
Movalis should be used with caution in elderly patients who often have impaired renal, hepatic or cardiac function. NSAIDs can contribute to the retention of sodium, potassium and water and weaken the natriuretic effect of diuretics. As a result, in the presence of predisposing factors, the appointment of NSAIDs can lead to progression of heart failure and hypertension.
Influence on ability to drive motor transport and control mechanisms
During the period of treatment, when there is a violation of visual acuity, dizziness or drowsiness, it is necessary to refrain from driving vehicles and practicing potentially dangerous activities that require increased concentration of attention and quickness of psychomotor reactions.

Drug Interactions

With the simultaneous appointment of more than one drug from the group of NSAIDs as a result of synergies, the risk of developing ulcerative lesions or bleeding from the gastrointestinal tract may increase.
It has been reported that NSAIDs increase lithium levels in plasma. It is recommended to repeat the determination of lithium concentration in plasma at the beginning and end of treatment, as well as after changing the dose of Movalis.
If administered concurrently with potentially myelotoxic drugs, cytopenia may develop. Movalis may enhance the hematological toxicity of Methotrexate.In such cases, monitoring of the number of blood cells is necessary.
There are reports that NSAIDs reduce the effectiveness of intrauterine contraceptives.
In the treatment of NSAIDs, there is the potential for the development of acute renal failure in patients with dehydration. Patients who use Movalis at the same time as diuretics should receive a sufficient amount of fluid; before starting treatment with Movalis, they must determine the functional state of the kidneys.
During NSAID therapy, there was a decrease in the effectiveness of antihypertensive agents (for example, beta-blockers, acetylcholinesterase inhibitors, vasodilators, diuretics) due to inhibition of the synthesis of prostaglandin-vasodilators.
Kolestiramin binds meloxicam in the gastrointestinal tract, which leads to accelerated removal of meloxicam from the body.
NSAIDs may indirectly, via renal prostaglandins, enhance cyclosporine nephrotoxicity. With simultaneous appointment of Movalis and cyclosporine, renal function should be monitored.
We can not exclude the possibility of drug interaction of meloxicam with hypoglycemic agents.
NSAIDs can cause sodium, potassium, liquid retention and weaken the effect of saluretics. As a result, prescription of NSAIDs in predisposed patients may lead to progression of heart failure and arterial hypertension.
Should take into account the possibility of pharmacokinetic interaction with the simultaneous appointment of meloxicam and drugs that reduce the activity or metabolized with the participation of isoenzymes CYP2C9 or CYP3A4.
No pharmacokinetic drug interactions were detected with simultaneous administration of meloxicam and antacids, cimetidine, Digoxin, Furosemide.

Treatment: gastric lavage and standard support measures. The specific antidote is unknown. During clinical trials, Kolestiramine has been shown to accelerate the elimination of meloxicam.

Store in a dark place at a temperature not higher than 25 ° C.